Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 08/24/2014
‘An emerging epidemic of acute hepatitis C threatens the country’s younger population, which experienced a significant hike in the number of cases during a recent 6-year period, according to a compound study that looked at trends of the disease among youth.’
‘The World Hepatitis Alliance has created HCV Quest, a global survey that provides a forum for patients with hepatitis C virus, according to an announcement on the European Association for the Study of the Liver website. The survey, designed by a focus group and in part by Markus Peck-Radosavljevic, MD, EASL secretary-general, is for patients with hepatitis C virus (HCV) and asks questions about their experiences with the virus, care and treatment.’
‘With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings. Called Project INSPIRE NYC, the new initiative arose from a partnership between The New York City Department of Health & Mental Hygiene (NYC DOHMH) and the Fund for Public Health, which together won a grant to fund it from the Centers for Medicare & Medicaid Services’ Health Care Innovation Awards program.’
‘A new study by researchers at Weill Cornell Medical College in Qatar (WCMC-Q) shows that there is a large geographic variation in the distribution of the hepatitis C virus (HCV) in Egypt. Egypt has the highest infection level of the disease in the world, with 14.7% of the population carrying HCV, but it is still not clear why this is so.’
‘Given the recent evolution of hepatitis C virus (HCV) treatment, starting with the 2011 introduction of Incivek and Victrelis and continuing with the late 2013 approval of Olysio and Sovaldi, it’s no surprise that payers now consider the HCV category nearly as important a management priority as cancer, rheumatoid arthritis (RA), or multiple sclerosis (MS). These are all high-spend disease states, and have become more so recently.’
‘Controversy over the price of Gilead’s hepatitis C (HCV) drug Sovaldi (sofosbuvir) continues. On Aug. 13, ACT UP New York (ACT UP NY) sent a letter to the U.S. Senate Finance Committee Chairman Ron Wyden (D-OR), demanding a 90% reduction in the price of Sovaldi and outlining two ways in which the government could “break Gilead’s monopoly” on the potent treatment.’